Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Primary Target

3-hydroxy-3-methylglutaryl-coenzyme A reductase

9

Histamine H1 receptor

316

Dopamine D2 receptor

311

DNA

282

Serotonin 2a (5-HT2a) receptor

237

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Approved Rx

6

Investigational

3

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

6

Not Provided

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1991

6

Unknown

3

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Unknown

9

Coronary heart disease mortality and cardiovascular events

6

Homozygous and heterozygous familial hypercholesterolemia

6

Hyperlipidemia

6

Familial hypercholesterolemia

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

9

Preventing

6

Palliative

3

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

6

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Merck

6

Sankyo

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

9

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

9

EPA CompTox

9

FDA UNII

9

PUBCHEM

9

SMS_ID

6

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ALIMENTARY TRACT AND METABOLISM

1

CARDIOVASCULAR SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

DRUGS USED IN DIABETES

1

LIPID MODIFYING AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS

1

LIPID MODIFYING AGENTS, COMBINATIONS

1

LIPID MODIFYING AGENTS, PLAIN

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Dipeptidyl peptidase 4 (DPP-4) inhibitors

1

HMG CoA reductase inhibitors

1

HMG CoA reductase inhibitors in combination with other lipid modifying agents

1

HMG CoA reductase inhibitors, other combinations

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

7

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 9 of 9 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

TENIVASTATIN

9L6M5TH46B

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First approved in 1991

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Solute carrier organic anion transporter family member 3A1

Solute carrier organic anion transporter family member 1B1

3-hydroxy-3-methylglutaryl-coenzyme A reductase

Cytochrome P450 3A4

HMG-CoA reductase

Conditions:

Coronary heart disease mortality and cardiovascular events

Homozygous and heterozygous familial hypercholesterolemia

Simvastatin is a HMG-CoA Reductase Inhibitor that is FDA approved for the treatment of hypercholesterolemia and for the reduction in the risk of cardiac heart disease mortality and cardiovascular events. It reduces levels of "bad" cholesterol (low-de...

nsity lipoprotein, or LDL) and triglycerides in the blood, while increasing levels of "good" cholesterol (high-density lipoprotein, or HDL). Common adverse reactions include abdominal pain, constipation, nausea, headache, upper respiratory infection. Cases of myopathy/rhabdomyolysis have been observed with simvastatin co-administered with lipid-modifying doses ( ≥ 1 g/day niacin) of niacin-containing products. The risk of myopathy, including rhabdomyolysis, is increased by concomitant administration of amiodarone, dronedarone, ranolazine, or calcium channel blockers such as verapamil, diltiazem, or amlodipine.

MEVINIC ACID

1R89KK61YI

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

HMG-CoA reductase

3-hydroxy-3-methylglutaryl-coenzyme A reductase

Conditions:

Triple-negative breast cancer

Familial hypercholesterolemia

Mevastatin (compactin or ML-236B) is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. This drug induces apoptosis and arrest of cancer cells in G1 phase. Therapeutic effects of mevastatin on serum level of lipoproteins and u...

nbiquinone-10 in patients with familial hypercholesterolemia were investigated. However, that study was discontinued. In addition, mevastatin was investigated for the treatment of melanoma. It was suggested, that mevastatin was unlikely to prevent melanoma at standard doses. However, higher doses could have a role to play in adjuvant therapy by inhibiting growth and invasion of melanoma cells. Also was revealed, that mevastatin increased histone deacetylase inhibitor, LBH589-induced cell death in triple-negative breast cancer (TNBC) cells.

SIMVASTATIN

AGG2FN16EV

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First approved in 1991

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Solute carrier organic anion transporter family member 3A1

Solute carrier organic anion transporter family member 1B1

3-hydroxy-3-methylglutaryl-coenzyme A reductase

Cytochrome P450 3A4

HMG-CoA reductase

Conditions:

Coronary heart disease mortality and cardiovascular events

Homozygous and heterozygous familial hypercholesterolemia

Simvastatin is a HMG-CoA Reductase Inhibitor that is FDA approved for the treatment of hypercholesterolemia and for the reduction in the risk of cardiac heart disease mortality and cardiovascular events. It reduces levels of "bad" cholesterol (low-de...

nsity lipoprotein, or LDL) and triglycerides in the blood, while increasing levels of "good" cholesterol (high-density lipoprotein, or HDL). Common adverse reactions include abdominal pain, constipation, nausea, headache, upper respiratory infection. Cases of myopathy/rhabdomyolysis have been observed with simvastatin co-administered with lipid-modifying doses ( ≥ 1 g/day niacin) of niacin-containing products. The risk of myopathy, including rhabdomyolysis, is increased by concomitant administration of amiodarone, dronedarone, ranolazine, or calcium channel blockers such as verapamil, diltiazem, or amlodipine.

TENIVASTATIN SODIUM

2L6JSY5YGL

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First approved in 1991

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Solute carrier organic anion transporter family member 3A1

Solute carrier organic anion transporter family member 1B1

3-hydroxy-3-methylglutaryl-coenzyme A reductase

Cytochrome P450 3A4

HMG-CoA reductase

Conditions:

Coronary heart disease mortality and cardiovascular events

Homozygous and heterozygous familial hypercholesterolemia

Simvastatin is a HMG-CoA Reductase Inhibitor that is FDA approved for the treatment of hypercholesterolemia and for the reduction in the risk of cardiac heart disease mortality and cardiovascular events. It reduces levels of "bad" cholesterol (low-de...

nsity lipoprotein, or LDL) and triglycerides in the blood, while increasing levels of "good" cholesterol (high-density lipoprotein, or HDL). Common adverse reactions include abdominal pain, constipation, nausea, headache, upper respiratory infection. Cases of myopathy/rhabdomyolysis have been observed with simvastatin co-administered with lipid-modifying doses ( ≥ 1 g/day niacin) of niacin-containing products. The risk of myopathy, including rhabdomyolysis, is increased by concomitant administration of amiodarone, dronedarone, ranolazine, or calcium channel blockers such as verapamil, diltiazem, or amlodipine.

TENIVASTATIN AMMONIUM

76RD797JAX

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First approved in 1991

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Solute carrier organic anion transporter family member 3A1

Solute carrier organic anion transporter family member 1B1

3-hydroxy-3-methylglutaryl-coenzyme A reductase

Cytochrome P450 3A4

HMG-CoA reductase

Conditions:

Coronary heart disease mortality and cardiovascular events

Homozygous and heterozygous familial hypercholesterolemia

Simvastatin is a HMG-CoA Reductase Inhibitor that is FDA approved for the treatment of hypercholesterolemia and for the reduction in the risk of cardiac heart disease mortality and cardiovascular events. It reduces levels of "bad" cholesterol (low-de...

nsity lipoprotein, or LDL) and triglycerides in the blood, while increasing levels of "good" cholesterol (high-density lipoprotein, or HDL). Common adverse reactions include abdominal pain, constipation, nausea, headache, upper respiratory infection. Cases of myopathy/rhabdomyolysis have been observed with simvastatin co-administered with lipid-modifying doses ( ≥ 1 g/day niacin) of niacin-containing products. The risk of myopathy, including rhabdomyolysis, is increased by concomitant administration of amiodarone, dronedarone, ranolazine, or calcium channel blockers such as verapamil, diltiazem, or amlodipine.

TENIVASTATIN CALCIUM

YNO268EI8T

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First approved in 1991

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Solute carrier organic anion transporter family member 3A1

Solute carrier organic anion transporter family member 1B1

3-hydroxy-3-methylglutaryl-coenzyme A reductase

Cytochrome P450 3A4

HMG-CoA reductase

Conditions:

Coronary heart disease mortality and cardiovascular events

Homozygous and heterozygous familial hypercholesterolemia

Simvastatin is a HMG-CoA Reductase Inhibitor that is FDA approved for the treatment of hypercholesterolemia and for the reduction in the risk of cardiac heart disease mortality and cardiovascular events. It reduces levels of "bad" cholesterol (low-de...

nsity lipoprotein, or LDL) and triglycerides in the blood, while increasing levels of "good" cholesterol (high-density lipoprotein, or HDL). Common adverse reactions include abdominal pain, constipation, nausea, headache, upper respiratory infection. Cases of myopathy/rhabdomyolysis have been observed with simvastatin co-administered with lipid-modifying doses ( ≥ 1 g/day niacin) of niacin-containing products. The risk of myopathy, including rhabdomyolysis, is increased by concomitant administration of amiodarone, dronedarone, ranolazine, or calcium channel blockers such as verapamil, diltiazem, or amlodipine.

TENIVASTATIN CALCIUM HYDRATE

QSL5L73L0O

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First approved in 1991

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Solute carrier organic anion transporter family member 3A1

Solute carrier organic anion transporter family member 1B1

3-hydroxy-3-methylglutaryl-coenzyme A reductase

Cytochrome P450 3A4

HMG-CoA reductase

Conditions:

Coronary heart disease mortality and cardiovascular events

Homozygous and heterozygous familial hypercholesterolemia

Simvastatin is a HMG-CoA Reductase Inhibitor that is FDA approved for the treatment of hypercholesterolemia and for the reduction in the risk of cardiac heart disease mortality and cardiovascular events. It reduces levels of "bad" cholesterol (low-de...

nsity lipoprotein, or LDL) and triglycerides in the blood, while increasing levels of "good" cholesterol (high-density lipoprotein, or HDL). Common adverse reactions include abdominal pain, constipation, nausea, headache, upper respiratory infection. Cases of myopathy/rhabdomyolysis have been observed with simvastatin co-administered with lipid-modifying doses ( ≥ 1 g/day niacin) of niacin-containing products. The risk of myopathy, including rhabdomyolysis, is increased by concomitant administration of amiodarone, dronedarone, ranolazine, or calcium channel blockers such as verapamil, diltiazem, or amlodipine.

MEVASTATIN

1UQM1K0W9X

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

HMG-CoA reductase

3-hydroxy-3-methylglutaryl-coenzyme A reductase

Conditions:

Triple-negative breast cancer

Familial hypercholesterolemia

Mevastatin (compactin or ML-236B) is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. This drug induces apoptosis and arrest of cancer cells in G1 phase. Therapeutic effects of mevastatin on serum level of lipoproteins and u...

nbiquinone-10 in patients with familial hypercholesterolemia were investigated. However, that study was discontinued. In addition, mevastatin was investigated for the treatment of melanoma. It was suggested, that mevastatin was unlikely to prevent melanoma at standard doses. However, higher doses could have a role to play in adjuvant therapy by inhibiting growth and invasion of melanoma cells. Also was revealed, that mevastatin increased histone deacetylase inhibitor, LBH589-induced cell death in triple-negative breast cancer (TNBC) cells.

MEVASTATIN HYDROXY ACID SODIUM

F346G86K5B

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

HMG-CoA reductase

3-hydroxy-3-methylglutaryl-coenzyme A reductase

Conditions:

Triple-negative breast cancer

Familial hypercholesterolemia

Mevastatin (compactin or ML-236B) is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. This drug induces apoptosis and arrest of cancer cells in G1 phase. Therapeutic effects of mevastatin on serum level of lipoproteins and u...

nbiquinone-10 in patients with familial hypercholesterolemia were investigated. However, that study was discontinued. In addition, mevastatin was investigated for the treatment of melanoma. It was suggested, that mevastatin was unlikely to prevent melanoma at standard doses. However, higher doses could have a role to play in adjuvant therapy by inhibiting growth and invasion of melanoma cells. Also was revealed, that mevastatin increased histone deacetylase inhibitor, LBH589-induced cell death in triple-negative breast cancer (TNBC) cells.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1